Skip to main content
Premium Trial:

Request an Annual Quote

Namocell, SingLab Technologies Ink Distribution Agreement for Singapore

NEW YORK – Namocell said on Monday that it has signed an agreement with SingLab Technologies to distribute its single-cell isolation systems in Singapore.

The Mountain View, California-based company provides single-cell sorting and dispensing platforms for research and therapeutics development.

"Advances in cell biology have created a new era of cell-based research and therapeutics," said SingLab CEO Michael Choi in a statement. "[Namocell's] benchtop low-pressure single-cell dispensers are designed to protect the viability and integrity of isolated cells for a wide range of downstream applications."

"There has been increasing demand for our single-cell dispenser systems in the Southeast Asia market," Junyu Lin, CEO of Namocell, said in a statement. "[SingLab's] strong technical expertise in cell-based R&D products and excellent customer service capabilities make them a great partner."

Financial terms of the agreement were not disclosed.

In March, Namocell signed an agreement with Germany-based Omni Life Science (OLS) to distribute the firm's single-cell dispensers in Germany and Austria.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.